BCR and chronic myelogenous leukemia, BCR-ABL1 positive: A landmark in targeted therapy was the discovery of the BCR-ABL fusion gene in chronic myelogenous leukemia (CML) and the subsequent development of imatinib, a BCR-ABL inhibitor [1].